Two of 768 genetic markers tested in 1,915 depressed patients taking citalopram were associated with the emergence of suicidal thoughts during treatment. The markers are in the genes GRIA3 and GRIK2, which both encode glutamate receptors. Of the two patients who attempted suicide in the study, one has provided a DNA sample and it contained the high-risk alleles for both genes. Laje et al. (p. 1530) point out that glutamate neurotransmission has previously been linked to the therapeutic response to antidepressants in prior work with this sample. Their findings come from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, which was sufficiently large to allow genetic analysis of treatment-emergent suicidal thoughts. Another large database, the population-based Mid-Atlantic Twin Registry, enabled Keller et al. (CME, p. 1521) to discover connections between specific types of life events and the particular symptoms of people who develop depression. Among 4,856 people who had depressive symptoms in the preceding year, those who had experienced the death of a loved one or a romantic breakup were more likely to feel sad, lose their appetite, and be unable to feel pleasure. Participants who had multiple depressive episodes had different symptoms during each episode, corresponding to the negative events in their lives at the time. Patients without identified adverse life events were more likely to report thoughts of self-harm, which suggests that other causes, such as the genetic predisposition described by Laje et al., might be more influential in determining suicidality. Dr. Elliot Gershon comments on these results in an editorial on p. 1460.